SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Pre-market
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
DiscoverTEVA
HealthcareNYQUSD

Teva Pharmaceutical Industries Limited

$0012345678900123456789.0012345678900123456789-2.1%
52w low (est.) $25.68$40.69 52w high (est.)
Market data
Market cap
USD37.47B
52-week range
USD14.99 – USD37.35
Beta (vs market)
0.86
Sector
Healthcare
Data quality
96/100
Valuation
P/E ratio
24.0x
DCF fair value
USD51.59
Margin of safety
+60.1%
Forward P/E
10.5x
PEG ratio
0.94
Quality & efficiency
Moat score
56/100
Return on equity
21.6%
Profit margin
9.0%
Debt / equity
2.06
Growth & analysts
Revenue growth (YoY)
+2.3%
Analyst target
USD40.90
Target upside
+26.9%
Analysts covering
10

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Valuation

ValueGrowthProfitHealthIncome37QUALITY
Overall Rating
70
Strong Buy
Strong Buy

Derived from filed metrics · High confidence (96% of the inputs available)

Moat Score56
DCF Intrinsic Value
USD51.59+60.1% upside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
USD37.47B
P/E Ratio
24.0
Dividend Yield
0.00%
Revenue Growth
+2.3%
Profit Margin
9.0%
ROE
21.6%
Debt / Equity
2.06
Beta
0.86
vs Healthcare sector:P/E 24 vs 28 · cheaperMoat 56 vs 7Yield 0.00% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · TEVA